CML Experts in Canada - Experts LMC au Canada
Attention
Pour accéder aux liens ci-dessus, vous avez besoin du mot de passe du patient LMC, aussi appelé CMLer's Password. Ce mot de passe restera actif durant toute la session sur ce site web.
Pour accéder aux liens ci-dessus, vous avez besoin du mot de passe du patient LMC, aussi appelé CMLer's Password. Ce mot de passe restera actif durant toute la session sur ce site web.
( Note: this list is not exhaustive)
CML Experts in Quebec - Experts LMC au Quebec
(Montreal - Quebec City - Sherbrooke)
(Montreal - Quebec City - Sherbrooke)
|
Hôpital Général Juif de Montréal
Hôpital Général Juif de Montréal Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Royal-Victoria (Montréal) Centre hospitalier universitaire de Sherbrooke Centre hospitalier universitaire de Sherbrooke Hôpital de l’Enfant-Jésus (Ville de Québec) CHU Pavillon Hôtel-Dieu de Québec (Québec) |
Vertical Divider
Attention
To access this module, you need to get your CMLer's password. This password stay active for all the session on the website.
To access this module, you need to get your CMLer's password. This password stay active for all the session on the website.
CML Experts in Ontario - Experts LMC en Ontario
|
Princess Margaret Hospital (Toronto)
Princess Margaret Cancer Centre (Toronto) Ottawa Hospital |
Vertical Divider
CML Experts in British Columia- Experts LMC en Colombie Britannique
Dr. Donna L. Forrest
Dr. John Shepherd
Dr. Kirk Schultz
Dr. David Sanford
CML Experts in Nova Scotia- Experts LMC en Nouvelle Écosse
Dr. Conrad Vincent Fernandez
Dr. Conrad Vincent Fernandez
CLINICAL TRIALS
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
